Henrietta Lacks

Henrietta Lacks, a Black woman treated for cervical cancer at Johns Hopkins Hospital in 1951, was the unwitting source of the HeLa cell line, the first immortal human cells and the foundation of vast areas of modern biology and medicine. Her tissue made possible polio vaccines, cancer therapies, in‑vitro fertilization and gene mapping, even as her name and family were excluded from credit, consent, and benefit. The archive holds her not as a passive victim of exploitation but as a central, if unacknowledged, author of the biomedical revolution: without her cells’ unique properties, the laboratory systems that drove mid‑century medicine would not have existed in the form we know.

1.Life and the Making of HeLa

Henrietta Lacks was born Loretta Pleasant in Roanoke, Virginia, in 1920 and raised in rural Clover, Virginia, in a Black tobacco‑growing community shaped by Jim Crow and sharecropping. In 1941 she moved with her husband David Lacks to Turner Station, a Black working‑class neighborhood outside Baltimore, as part of the wartime migration that brought Black labor into industrial cities.

In January 1951, at age 30, she sought care at Johns Hopkins Hospital, one of the few institutions in Baltimore that treated Black patients, for what she described as a “knot” in her womb. Physicians diagnosed an aggressive cervical carcinoma and began radium treatment. During her clinical visits, portions of her tumor and healthy cervical tissue were taken and passed without her knowledge to researcher George Gey’s laboratory, in keeping with prevailing practice that treated patient tissue as hospital property rather than something requiring consent.

In Gey’s lab, technicians cultured the tumor cells in glass flasks. Where most human cells died after a few divisions, Lacks’s cancer cells divided rapidly and continuously, thriving in vitro. The lab labeled them “HeLa,” using the first two letters of her first and last names, and began distributing them to other researchers. Henrietta Lacks herself died on October 4, 1951, at Johns Hopkins, unaware that her cells had already begun a second life in laboratories around the world.

2.What Her Cells Built

The HeLa cell line became the first widely available immortal human cell line and quickly turned into an indispensable research tool. Scientists used HeLa cells to test Jonas Salk’s polio vaccine, allowing controlled experiments on viral infection and immunity that underwrote mass vaccination programs in the 1950s. HeLa cells were central to the emerging fields of virology and cell biology; they enabled studies of cancer growth, radiation damage, toxicology, and the effects of new chemotherapies under standardized conditions.

Beyond infectious disease and oncology, HeLa cells helped build in‑vitro fertilization techniques, contributed to gene mapping through somatic cell hybridization, and were sent into space to study how human cells respond to zero gravity. Commercial culture collections and biotech firms grew profitable businesses around HeLa and derivative lines, selling vials of her cells to laboratories and companies worldwide. The archive holds that this infrastructure—labs, protocols, commercial supply chains—rests on the biological specificity of Henrietta Lacks’s tissue. Without HeLa’s particular robustness, the scale and speed of postwar cell‑based research would have been markedly different.

3.Erasure, Exploitation, and Family Discovery

For decades, the name behind HeLa was masked or misrepresented in scientific publications, which often referred only to an anonymous “HeLa” line or printed incorrect names and biographical details. Within the dominant record, the cell line was treated as a neutral laboratory tool, detached from the Black woman whose cancer and care context made it possible.

Her family first learned of the cells’ existence in the 1970s, when researchers contacted them seeking blood samples to study unexplained HeLa contamination across cell lines. They were stunned to hear that part of Henrietta was still “alive” in laboratories. The communication was technical, confusing, and devoid of meaningful consent or explanation; it did not come with offers of compensation or shared control, even as companies profited from the distribution of HeLa.

The archive reads this silence not as absence of authorship but as evidence of an ethical regime that normalized the harvesting of Black patients’ tissue without consent and treated their bodies as unowned resources. The erasure of Henrietta’s name from the HeLa story for more than two decades, and the later resistance to family demands for recognition, exemplify how race, class, and institutional power shape whose contributions are legible in the scientific canon.

4.Reclaiming the Name and the Question of Credit

From the late twentieth century onward, journalists, historians, and the Lacks family themselves worked to bring her story into public view. Church records, family oral histories, and Black community memory in Turner Station and Clover preserved details of her life—her work, faith, and character—that standard biomedical narratives had ignored in favor of lab procedures and laboratory lore.

In the 1990s and 2000s, renewed attention to medical ethics and racial injustice pushed institutions to confront the case. Johns Hopkins issued public statements acknowledging the hospital’s role, while insisting that practices of tissue collection reflected the norms of the time. The Lacks family, with support from Black legal advocates and bioethicists, pressed for recognition, some forms of compensation, and greater control over the genetic data derived from HeLa.

The archive distinguishes between financial ownership and authorship. Patent and intellectual property regimes have treated HeLa‑based technologies as the achievement of laboratories and firms, granting them exclusive rights. Yet the enabling biological invention—cells that could grow indefinitely, survive transport, and serve as a proxy for human tissue—was located in Henrietta’s body and the conditions of her illness. The legal system did not recognize that as inventorship; this archive does, while making clear that her consent was never sought.

5.HeLa, Consent, and the Ongoing Standard of Care

Henrietta Lacks’s story has become a central case in debates over informed consent, tissue ownership, and racial justice in medicine. It is now taught in medical schools and ethics courses as a cautionary narrative about non‑consensual use of patient materials and the disparities in how benefits and harms of research are distributed.

For Black communities, the case resonates with a longer history—from grave robbing for medical training to the Tuskegee syphilis study—where Black bodies were used to build knowledge while Black people were denied full personhood in clinical decision‑making. Henrietta’s descendants have used public storytelling, church gatherings, and memorial events as instruments of repair, reconnecting the global HeLa story to its Black family and community origins.

The archive holds her legacy as active and unfinished. Scientific institutions now acknowledge her name, and some have entered into agreements with the family regarding genomic data. Yet the original imbalance—decades of profit and prestige built atop uncompensated Black tissue—remains. Naming Henrietta Lacks as an author of the HeLa era is a step toward accountability and toward an honest record of who built modern biomedicine.

The family archive is admissible here. Photographs, letters, deeds, church programs, funeral bulletins, business records, recordings — the things that were kept when no institution was keeping them. A keeper reviews everything before it is admitted, and your name stays on it.

7.References